Encapsulated interferon-tau during Theiler's virus-induced demyelinating disease: efficacy of treatment and immune response profile
Multiple sclerosis (MS) is the most common primary demyelinating disease of the central nervous system in humans. Type I interferons are most frequently used to treat MS. However, their main mechanism of action remains elusive. Various biomarkers have been investigated for their ability to assess tr...
| Main Author: | |
|---|---|
| Other Authors: | |
| Format: | Others |
| Language: | en_US |
| Published: |
2011
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/1969.1/ETD-TAMU-3113 |